Hepatitis C virus coinfection and superinfection

Journal of Infectious Diseases

Volumn 195, Issue 4, 2007, Pages 519-524

  Blackard, Jason T ^a   Sherman, Kenneth E ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS C VACCINE;

CELL GROWTH; DRUG EFFICACY; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION RISK; MIXED INFECTION; NONHUMAN; PATIENT COMPLIANCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REINFECTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; RNA VIRUS; SEROCONVERSION; SUPERINFECTION; TREATMENT OUTCOME; VIREMIA; VIRUS IMMUNITY; VIRUS REPLICATION; VIRUS RESISTANCE;

ANIMALS; HEPACIVIRUS; HEPATITIS C; HUMANS; SUPERINFECTION; VARIATION (GENETICS);

EID: 33846809495     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/510858     Document Type: Review

References (63)

1. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282:103-7.
2. Simmonds P. Genetic diversity and evolution of hepatitis C virus - 15 years on. J Gen Virol 2004; 85:3173-88.
3. Hnatyszyn HJ. Chronic hepatitis C and genotyping: the clinical significance of determining HCV genotypes. Antivir Ther 2005; 10:1-11.
4. Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000; 33:106-15.
5. Adinolfi L, Gambardella M, Andreana A, Tripodi M, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33:1358-64.
6. Farci P, Alter HJ, Govindarajan S, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992; 258:135-40.
7. Prince AM, Brotman B, Huima T, Pascual D, Jaffery M, Inchauspe G. Immunity in hepatitis C infection. J Infect Dis 1992; 165:438-43.
8. Prince AM, Brotman B, Lee DH, et al. Protection against chronic hepatitis C virus infection after rechallenge with homologous, but not heterologous, genotypes in a chimpanzee model. J Infect Dis 2005; 192:1701-9.
9. Sylvestre DL. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002; 67:117-23.
10. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001; 34:188-93.
11. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37:443-51.
12. Van Thiel DH, Friedlander L, Molloy PJ, Fagiuoli S, Kania RJ, Caraceni P. Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness. Eur J Gastroenterol Hepatol 1995; 7:165-8.
13. Neri S, Bruno CM, Abate G, et al. Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b. Clin Ther 2002; 24:1627-35.
14. Dalgard O, Bjoro K, Hellum K, et al. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Eur Addict Res 2002; 8:45-9.
15. Van Thiel DH, Anantharaju A, Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. Am J Gastroenterol 2003; 98:2281-8.
16. Robaeys G, Van Vlierberghe H, Mathei C, Van Ranst M, Bruckers L, Buntinx F. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Eur J Gastroenterol Hepatol 2006; 18:159-66.
17. Stoove MA, Gifford SM, Dore GJ. The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug Alcohol Depend 2005; 77:81-6.
18. NIH consensus statement on management of hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19:1-46.
19. Mehta SH, Cox A, Hoover DR, et al. Protection against persistence of hepatitis C. Lancet 2002; 359:1478-83.
20. Kao JH, Lai MY, Chen PJ, Chen DS. Probable reinfection with hepatitis C virus in a chronic hepatitis C patient with a sustained response to combination therapy. J Formos Med Assoc 2001; 100:824-8.
21. Asselah T, Vidaud D, Doloy A, et al. Second infection with a different hepatitis C virus genotype in a intravenous drug user during interferon therapy. Gut 2003; 52:900-2.
22. Smith DM, Richman DD, Little SJ. HIV superinfection. J Infect Dis 2005; 192:438-44.
23. Kalinina O, Norder H, Magnius LO. Full-length open reading frame of a recombinant hepatitis C virus strain from St. Petersburg: proposed mechanism for its formation. J Gen Virol 2004; 85:1853-7.
24. Noppornpanth S, Lien T, Poovorawan Y, Smits S, Osterhaus A, Haagmans B. Identification of a naturally occurring recombinant genotype 2/6 hepatitis C virus. J Virol 2006; 80:7569-77.
25. Colina R, Casane D, Vasquez S, et al. Evidence of intratypic recombination in natural populations of hepatitis C virus. J Gen Virol 2004; 85:31-7.
26. Bourliere M, Barberin JM, Rotily M, et al. Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users. J Viral Hepat 2002; 9:62-70.
27. Bowden S, McCaw R, White PA, Crofts N, Aitken CK. Detection of multiple hepatitis C virus genotypes in a cohort of injecting drug users. J Viral Hepat 2005; 12:322-4.
28. Chen YD, Liu MY, Yu WL, et al. Mix-infections with different genotypes of HCV and with HCV plus other hepatitis viruses in patients with hepatitis C in China. World J Gastroenterol 2003; 9:984-92.
29. Herring B, Page-Shafer K, Tobler L, Delwart E. Frequent hepatitis C virus superinfection in injection drug users. J Infect Dis 2004; 190:1396-1403.
30. Qian KP, Natov SN, Pereira BJ, Lau JY. Hepatitis C virus mixed genotype infection in patients on haemodialysis. J Viral Hepat 2000; 7:153-60.
31. Schijman A, Colina R, Mukomolov S, et al. Comparison of hepatitis C viral loads in patients with or without coinfection with different genotypes. Clin Diagn Lab Immunol 2004; 11:433-5.
32. Schroter M, Feucht HH, Zollner B, Schafer P, Laufs R. Multiple infections with different HCV genotypes: prevalence and clinical impact. J Clin Virol 2003; 27:200-4.
33. van Asten L, Prins M. Infection with concurrent multiple hepatitis C virus genotypes is associated with faster HIV disease progression. AIDS 2004; 18:2319-24.
34. White PA, Li Z, Zhai X, Marinos G, Rawlinson WD. Mixed viral infection identified using heteroduplex mobility analysis (HMA). Virology 2000; 271:382-9.
35. Kao JH, Chen PJ, Lai MY, et al. Mixed infections of hepatitis C virus as a factor in acute exacerbations of chronic type C hepatitis. J Infect Dis 1994; 170:1128-33.
36. Soriano V, Ramos B, Nunez M, et al. Failure of hepatitis C therapy in HIV-coinfected drug users is not due to a shift in hepatitis C virus genotype. J Infect Dis 2005; 192:1245-8.
37. Roque-Afonso A, Ducoulombier D, Di Liberto G, et al. Compartmentalization of hepatitis C virus genotypes between plasma and peripheral blood mononuclear cells. J Virol 2005; 79:6349-57.
38. Di Liberto G, Roque-Afonso AM, Kara R, et al. Clinical and therapeutic implications of hepatitis C virus compartmentalization. Gastroenterology 2006; 131:76-84.
39. Widell A, Mansson S, Persson NH, Thysell H, Hermodsson S, Blohme I. Hepatitis C superinfection in hepatitis C virus (HCV)-infected patients transplanted with an HCV-infected kidney. Transplantation 1995; 60:642-7.
40. Okamoto H, Mishiro S, Tokita H, Tsuda F, Miyakawa Y, Mayumi M. Superinfection of chimpanzees carrying hepatitis C virus of genotype II/1b with that of genotype III/2a or I/1a. Hepatology 1994; 20:1131-6.
41. Lai ME, Mazzoleni AP, Argiolu F, et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 1994; 343:388-90.
42. Kao JH, Chen PJ, Wang JT, et al. Superinfection by homotypic virus in hepatitis C virus carriers: studies on patients with post-transfusion hepatitis. J Med Virol 1996; 50:303-8.
43. Kao JH, Chen PJ, Lai MY, Chen DS. Superinfection of heterologous hepatitis C virus in a patient with chronic type C hepatitis. Gastroenterology 1993; 105:583-7.
44. Accapezzato D, Fravolini F, Casciaro MA, Paroli M. Hepatitis C flare due to superinfection by genotype 4 in an HCV genotype 1b chronic carrier. Eur J Gastroenterol Hepatol 2002; 14:879-81.
45. Laskus T, Wang L, Radkowski M, et al. Exposure of hepatitis C virus (HCV) RNA-positive recipients to HCV RNA-positive blood donors results in rapid predominance of a single donor strain and exclusion and/or suppression of the recipient strain. J Virol 2001; 75:2059-66.
46. Backmund M, Meyer K, Edlin B. Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis 2004; 39:1540-3.
47. den Hollander JG, Rijnders BJ, van Doornum GJ, van der Ende ME. Sexually transmitted reinfection with a new hepatitis C genotype during pegylated interferon and ribavirin therapy. AIDS 2005; 19:639-40.
48. Proust B, Dubois F, Bacq Y, et al. Two successive hepatitis C virus infections in an intravenous drug user. J Clin Microbiol 2000; 38:3125-7.
49. Eyster ME, Sherman KE, Goedert JJ, Katsoulidou A, Hatzakis A. Prevalence and changes in hepatitis C virus genotypes among multi-transfused persons with hemophilia. The Multicenter Hemophilia Cohort Study. J Infect Dis 1999; 179:1062-9.
50. Toyoda H, Fukuda Y, Hayakawa T, et al. Presence of multiple genotype-specific antibodies in patients with persistent infection with hepatitis C virus (HCV) of a single genotype: evidence for transient or occult superinfection with HCV of different genotypes. Am J Gastroenterol 1999; 94:2230-6.
51. Pujol FH, Devesa M, Loureiro CL, Capriles F, Liprandi F. Turnover of hepatitis C virus genotypes in hemodialysis patients. Arch Virol 1998; 143:823-7.
52. Laskus T, Wang LF, Radkowski M, Nowicki M, Wilkinson J, Rakela J. Exposure of hepatitis C virus-negative recipients to ≥2 infected blood donors. J Infect Dis 2001; 183:666-9.
53. Jarvis LM, Watson HG, McOmish F, Peutherer JF, Ludlam CA, Simmonds P. Frequent reinfection and reactivation of hepatitis C virus genotypes in multitransfused hemophiliacs. J Infect Dis 1994; 170:1018-22.
54. Giannini C, Giannelli F, Monti M, et al. Prevalence of mixed infection by different hepatitis C virus genotypes in patients with hepatitis C virus-related chronic liver disease. J Lab Clin Med 1999; 134:68-73.
55. Calvo PL, Kansopon J, Sra K, et al. Hepatitis C virus heteroduplex tracking assay for genotype determination reveals diverging genotype 2 isolates in Italian hemodialysis patients. J Clin Microbiol 1998; 36:227-33.
56. Dove L, Phung Y, Bzowej N, Kim M, Monto A, Wright TL. Viral evolution of hepatitis C in injection drug users. J Viral Hepat 2005; 12:574-83.
57. Hu YW, Balaskas E, Furione M, et al. Comparison and application of a novel genotyping method, semiautomated primer-specific and mispair extension analysis, and four other genotyping assays for detection of hepatitis C virus mixed-genotype infections. J Clin Microbiol 2000; 38:2807-13.
58. Evans MJ, Rice CM, Goff SP. Genetic interactions between hepatitis C virus replicons. J Virol 2004; 78:12085-9.
59. Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11:791-6.
60. Cai Z, Zhang C, Chang KS, et al. Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNA-transfected human hepatoma cells. J Virol 2005; 79:13963-73.
61. Zhong J, Gastaminza P, Cheng G, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 2005; 102:9294-9.
62. Heller T, Saito S, Auerbach J, et al. An in vitro model of hepatitis C virion production. Proc Natl Acad Sci USA 2005; 102:2579-83.
63. Lindenbach B, Evans M, Syder A, et al. Complete replication of hepatitis C virus in cell culture. Science 2005; 309:623-6.